跳至主要内容
临床试验/EUCTR2018-000886-35-ES
EUCTR2018-000886-35-ES进行中(未招募)1 期

Evaluation of safety, feasibility and preliminary efficacy of MSCs from third party donors in the treatment of patients with osteonecrosis of the femoral head after allogeneic Stem Cell Transplantation (AloFem) - AloFem

Enrique Gomez-Barrena0 个研究点目标入组 7 人开始时间: 2018年4月9日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
7

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age: 8 to 55, both sexes
  • - Patients having received allogeneic haematological stem cell transplant (HSCT), due to hematologic diseases, in remission. The patient may be or have been under immunosupression.
  • - Osteonecrosis of the femoral head (MRI diagnosis): Ficat and Arlet 0, 1, 2 or 3 or ARCO stages 0, I, IIA, IIB, IIC, IIIA, IIIB, IIIC or Steinberg stages 0, I, II, III.
  • - Able to provide informed consent, and signed informed consent (by themselves or legal representative)
  • - Medical health care coverage
  • - Able to understand and accept the study constraints (by themselves or legal representative)
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 4
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range 3
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Disease in relapse
  • - Active infection of any location and aetiology
  • - Surgical contraindication of any cause
  • - Pregnancy, breastfeeding women and women who are of childbearing age and not practicing adequate birth control.
  • - Stage 4 (Ficat and Arlet) or IV and above (Steinberg) or ARCO IV, with severe femoral head osteonecrosis associated to acetabular changes, primarily based on diagnosis by imaging (X-Rays, MRI)
  • - Flattening or collapse of the femoral head (Steinberg stage IV) or articular cartilage collapse at the time of core decompression surgery
  • - Any tumour infiltration of the femoral head and/or neck
  • - Other tumour infiltration with short-term life risk
  • - Stress or pathological fracture of the femoral neck
  • - Traumatic osteonecrosis
  • - Non-osteonecrosis metabolic bone diseases (particularly Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism, monostotic or polyostotic fibrous dysplasia, McCune-Albright syndrome and osteopetrosis)
  • - Any active bisphosphonate treatment (or 3 months before the trial, except in case they are used in the treatment of an acute disorder that requires prompt management, e.g., severe hypercalcemia, severe bone pain).
  • - Any evidence of HIV, Hepatitis B or Hepatitis C infection (confirmed by serology or PCR)
  • - Known allergies to products involved in the production process of MSC
  • - History of regular alcohol consumption exceeding 2 drinks/day (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening and/or history of illicit drug use
  • - MRI incompatible internal devices (pacemakers, aneurysm clips, etc.)
  • - Impossibility to meet at the appointments for the clinical follow up

研究者

发起方
Enrique Gomez-Barrena

相似试验